INDIAGLYCO India Glycols Q2 FY26 results (Jul–Sep 2025) and concall
India Glycols delivered a strong Q2 FY26 performance, marked by robust growth in gross and net revenues, and significant expansion in EBITDA and PAT margins. This growth was primarily driven by the Biofuels and Potable Spirits segments, which saw substantial sales increases and margin improvements. The company also outlined plans for significant debt reduction and strategic focus on high-margin performance chemicals, despite a weak quarter for the overall chemicals business and challenges in Ennature Biopharma.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 13.5%, net profit up 38.5% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 961 | 975 | 863 | 1,040 | 1,091 +14% |
| EBITDA | 116 | 124 | 144 | 148 | 158 +36% |
| Net profit | 39 | 44 | 50 | 53 | 54 +38% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
